New Australian PBS Listing for Brocnhitol
Filed with ASX · · 3 pages · English
Earlier from Syntara
- Pharmaxis Acquires Control, Increases Stake in LOXL2 Program
- Boehringer Initiating Phase 2a Study Diabetic Retinopathy
- Antifibrotic LOXL2 Program Clears Preclinical Development
- Boehringer Ingelheim Initiates Phase IIa Study in NASH
- Positive Recommendation for Broader Bronchitol Access in Aus
Later from Syntara
- Pharmaxis Earns A$15 Million Milestone Payment
- Quarterly Shareholder Update - March 2018
- LOXL2 Program Attracts Strong Partner Interest at BIO18
- Quarterly Shareholder Update - June 2018
- Trading Halt Announcement - System Upgrade
Follow Syntara into a list and get an email when it puts out news.
Follow Syntara